Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Total Debt (2018 - 2025)

China SXT Pharmaceuticals has reported Total Debt over the past 8 years, most recently at $73102.0 for Q3 2025.

  • For Q3 2025, Total Debt fell 99.03% year-over-year to $73102.0; the TTM value through Sep 2025 reached $73102.0, down 99.03%, while the annual FY2025 figure was $105045.0, 82.78% down from the prior year.
  • Total Debt for Q3 2025 was $73102.0 at China SXT Pharmaceuticals, down from $105045.0 in the prior quarter.
  • Over five years, Total Debt peaked at $12.2 million in Q1 2021 and troughed at $11404.0 in Q1 2022.
  • A 5-year average of $2.6 million and a median of $527743.0 in 2023 define the central range for Total Debt.
  • Biggest five-year swings in Total Debt: surged 13819.33% in 2021 and later plummeted 99.91% in 2022.
  • Year by year, Total Debt stood at $2.1 million in 2021, then plummeted by 99.46% to $11404.0 in 2022, then soared by 4527.7% to $527743.0 in 2023, then surged by 1332.97% to $7.6 million in 2024, then tumbled by 99.03% to $73102.0 in 2025.
  • Business Quant data shows Total Debt for SXTC at $73102.0 in Q3 2025, $105045.0 in Q1 2025, and $7.6 million in Q3 2024.